Lv4
700 积分 2023-03-16 加入
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
3个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
4个月前
已完结
Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer
4个月前
已完结
乳腺癌类器官在临床及转化应用中的进展
4个月前
已完结
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
5个月前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
5个月前
已完结
Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer
5个月前
已完结
An MRI-pathology foundation model for noninvasive diagnosis and grading of prostate cancer
6个月前
已完结
Immunotherapy in the neoadjuvant treatment of hormone receptor-positive/HER2-negative early breast cancer: novel approaches and future perspectives
8个月前
已关闭
Trastuzumab cardiotoxicity: FDA review of four adjuvant breast cancer clinical trials leading to trastuzumab marketing approvals
8个月前
已关闭
皖公网安备34019202002308
